271 related articles for article (PubMed ID: 32389747)
1. The Longitudinal Assessment of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimer's Disease and Their Association With White Matter Hyperintensities in the National Alzheimer's Coordinating Center's Uniform Data Set.
Anor CJ; Dadar M; Collins DL; Tartaglia MC
Biol Psychiatry Cogn Neurosci Neuroimaging; 2021 Jan; 6(1):70-78. PubMed ID: 32389747
[TBL] [Abstract][Full Text] [Related]
2. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
[TBL] [Abstract][Full Text] [Related]
3. White matter hyperintensities and neuropsychiatric symptoms in mild cognitive impairment and Alzheimer's disease.
Misquitta K; Dadar M; Louis Collins D; Tartaglia MC;
Neuroimage Clin; 2020; 28():102367. PubMed ID: 32798911
[TBL] [Abstract][Full Text] [Related]
4. White Matter Hyperintensities and Cognition in Mild Cognitive Impairment and Alzheimer's Disease: A Domain-Specific Meta-Analysis.
van den Berg E; Geerlings MI; Biessels GJ; Nederkoorn PJ; Kloppenborg RP
J Alzheimers Dis; 2018; 63(2):515-527. PubMed ID: 29630548
[TBL] [Abstract][Full Text] [Related]
5. White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia.
Dadar M; Manera AL; Ducharme S; Collins DL
Neurobiol Aging; 2022 Mar; 111():54-63. PubMed ID: 34968832
[TBL] [Abstract][Full Text] [Related]
6. Topographical differences in white matter hyperintensity burden and cognition in aging, MCI, and AD.
Kamal F; Morrison C; Maranzano J; Zeighami Y; Dadar M
Geroscience; 2023 Feb; 45(1):1-16. PubMed ID: 36229760
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities.
Burke SL; Hu T; Fava NM; Li T; Rodriguez MJ; Schuldiner KL; Burgess A; Laird A
J Women Aging; 2019; 31(2):140-164. PubMed ID: 29319430
[TBL] [Abstract][Full Text] [Related]
8. The Associations Between Serum Insulin-like Growth Factor-I, Brain White Matter Volumes, and Cognition in Mild Cognitive Impairment and Alzheimer's Disease.
Horvath A; Quinlan P; Eckerström C; Åberg ND; Wallin A; Svensson J
J Alzheimers Dis; 2024; 99(2):609-622. PubMed ID: 38701139
[TBL] [Abstract][Full Text] [Related]
9. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?
Provenzano FA; Muraskin J; Tosto G; Narkhede A; Wasserman BT; Griffith EY; Guzman VA; Meier IB; Zimmerman ME; Brickman AM;
JAMA Neurol; 2013 Apr; 70(4):455-61. PubMed ID: 23420027
[TBL] [Abstract][Full Text] [Related]
10. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
11. Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study.
Wang YL; Chen W; Cai WJ; Hu H; Xu W; Wang ZT; Cao XP; Tan L; Yu JT;
J Alzheimers Dis; 2020; 73(2):759-768. PubMed ID: 31839612
[TBL] [Abstract][Full Text] [Related]
12. Associations Between Hyperactive Neuropsychiatric Symptoms and Brain Morphology in Mild Cognitive Impairment and Alzheimer's Disease.
El Haffaf LM; Ronat L; Cannizzaro A; Hanganu A;
J Alzheimers Dis; 2024; 97(2):841-853. PubMed ID: 38143342
[TBL] [Abstract][Full Text] [Related]
13. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia.
Siafarikas N; Alnæs D; Monereo-Sanchez J; Lund MJ; Selbaek G; Stylianou-Korsnes M; Persson K; Barca ML; Almdahl IS; Fladby T; Aarsland D; Andreassen OA; Westlye LT
Int Psychogeriatr; 2021 Nov; 33(11):1217-1228. PubMed ID: 34399870
[TBL] [Abstract][Full Text] [Related]
15. Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.
Chan CK; Pettigrew C; Soldan A; Zhu Y; Wang MC; Albert M; Rosenberg PB;
J Alzheimers Dis; 2022; 86(3):1415-1426. PubMed ID: 35213370
[TBL] [Abstract][Full Text] [Related]
16. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
[TBL] [Abstract][Full Text] [Related]
17. Association of white matter hyperintensity measurements on brain MR imaging with cognitive status, medial temporal atrophy, and cardiovascular risk factors.
Appel J; Potter E; Bhatia N; Shen Q; Zhao W; Greig MT; Raj A; Barker WW; Potter H; Schofield E; Wu Y; Loewenstein DA; Duara R
AJNR Am J Neuroradiol; 2009 Nov; 30(10):1870-6. PubMed ID: 19643919
[TBL] [Abstract][Full Text] [Related]
18. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Eloyan A; Thangarajah M; An N; Borowski BJ; Reddy AL; Aisen P; Dage JL; Foroud T; Ghetti B; Griffin P; Hammers D; Iaccarino L; Jack CR; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Nudelman K; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Rogalski E; Salloway S; Sha S; Turner RS; Wingo TS; Wolk DA; Womack K; Beckett L; Gao S; Carrillo MC; Rabinovici G; Apostolova LG; Dickerson B; Vemuri P;
Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S89-S97. PubMed ID: 37491599
[TBL] [Abstract][Full Text] [Related]
19. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
[TBL] [Abstract][Full Text] [Related]
20. CD163-Mediated Small-Vessel Injury in Alzheimer's Disease: An Exploration from Neuroimaging to Transcriptomics.
Chen Y; Lu P; Wu S; Yang J; Liu W; ; Zhang Z; Xu Q
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
